DCTH

Steven A. J. Salamon

Known title: DirectorCIK: 0001623082

Steven A. J. Salamon's purchase track record

How the stock did after each of Steven A. J. Salamon's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.

Purchases measured
6
of 6 since December 30, 2021
Stock higher 6 months later
33%
3 months: 33%
Median 6-month return
-43.4%
3 months: -9.5%
Beat the S&P 500
33%
median -29.7% vs. index
PurchaseStockAmount3 months6 months
3/19/2024DCTH$100K+78.5%+119.2%
12/14/2022DCTH$55K+22.2%+80.8%
5/12/2022DCTH$55K-4.3%-40.0%
4/19/2022DCTH$10K-38.9%-53.0%
4/6/2022DCTH$39K-40.2%-48.9%
12/30/2021DCTH$15K-14.7%-46.8%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 26, 2026

Veracyte stock moves; DCTH shows no related news. Recent news coverage focuses on Veracyte (VCYT) rather than Delcath Systems (DCTH). There are no specific reports or announcements regarding DCTH in the provided data. The stock currently trades with a high trailing P/E ratio, while analyst targets remain above the current price level.

this person other insiders at DCTH

Transaction History

DCTH▼ Sell$4.0M
DCTH▼ Sell$2.5M
DCTH▼ Sell$0
DCTH▼ Sell$3843.3M
DCTH▲ Buy$100K
DCTH▲ Buy$55K
DCTH▲ Buy$25K
DCTH▲ Buy$29K
DCTH▲ Buy$10K
DCTH▲ Buy$10K
DCTH▲ Buy$16K
DCTH▲ Buy$6K
DCTH▲ Buy$6K
DCTH▲ Buy$15K

We use analytics to understand how market-wall is used. No personal data is sold.